Summary
This paper briefly surveys the control measures and tests which are carried out before, during and after manufacture of an i.v. immunoglobulin in order to assure the quality of the preparation. The quality requirements are determined by both the standards expected by physicians and patients and by the specifications of the registration authorities in the various countries.
A great deal of know-how and considerable technical investment is required to match these requirements. Furthermore a comprehensive quality assurance programme is compulsory: It begins with the careful collection and analysis of each single blood donation, continues through all the manufacturing stages and ends with the rigorous testing of every batch of the end product — an examination comprising 23 different tests.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
World Health Organization (1978) Requirements for the Collection, Processing and Quality Control of Blood and Blood Products. In: Technical Report Series No. 626
Code of Federal Regulations (1981) Title 21, Chapter I, Part 211. Current Good Manufacturing Practice for Finished Pharmaceuticals, p. 82. US Government Printing Office, Washington
Barandun S, Kistler P, Jeunet F, Isliker H (1962) Intravenous administration of human gamma globulin. Vox Sanguinis 7: 157–174
European Pharmacopoeia (1971) Vol. II: Immunoglobulinum normale humanum. p 247
Code of Federal Regulations (1982) Title 21, Chapter I, Part 640, Subpart J. Immune serum globulin (Human), p 137. US Government Printing Office, Washington
Tabor E, Aronson DL, Gerety RJ (1980) Removal of hepatitis B virus infectivity from Factor IX complex by hepatitis B immune globulin. Experiments in Chimpanzees. Lancet 2: 68–70
Tabor E, Gerety RJ (1979) Transmission of hepatitis B by immune serum globulin. Lancet 2: 1293
Finlayson JS (1981) Quality control of intravenous immunoglobulin preparations. In: UE Nydegger (ed) Immunotherapy: a guide to immunoglobulin prophylaxis and therapy. Academic Press, New York, pp 171–180
Barandun S, Morell A (1981) Adverse reactions to immunoglobulin preparations. In: UE Nydegger (ed) Immunotherapy: a guide to immunoglobulin prophylaxis and therapy. Academic Press, New York, pp 223–227
Sidiropoulos D, Böhme U, von Muralt G, Morell A, Barandun S (1981) Immunglobulinsubstitution bei der Behandlung der neonatalen Sepsis. Schweiz Med Wochenschr 111: 1649–1655
Skvaril F, Roth-Wicky B, Barandun S (1980) IgG subclasses in human gamma globulin preparations for intravenous use and their reactivity with Streptococcus protein A. Vox Sanguinis 38: 147–155
Barandun S (personal communcation)
Liehl E, Armerding D, Böckmann J (1980) Effektorfunktionen und protektive Wirkung von Standardimmunglobulin und Immunglobulin nach modifizierter milder Säurebehandlung. Infection 8: 194–198
Morell A, Schürch B, Ryser D, Hofer F, Skvaril F, Barandun S (1980) In vivo behaviour of gammaglobulin preparations. Vox Sanguinis 38: 272–283
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gardi, A. Quality control in the production of an immunoglobulin for intravenous use. Blut 48, 337–344 (1984). https://doi.org/10.1007/BF00319960
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00319960